Physician profile
Charles Flexner
NPI 1972546828
$132,827.22
in general payments reported to CMS, 2019-2025
6 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $2,550 · 2021: $16K · 2022: $29K · 2023: $13K · 2024: $5,470 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Travel and Lodging: $4,833 · Honoraria: $3,000 · Food and Beverage: $1,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,454.99 |
| Travel and Lodging | $4,832.52 |
| Honoraria | $3,000.00 |
| Food and Beverage | $1,633.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66,349.41 | 2019-2025 | |
| Viiv Healthcare Company | $37,891.48 | 2019-2023 | |
| Gilead Sciences, INC. | $11,367.16 | 2019-2025 | Sunlenca, Descovy |
| Theratechnologies INC. | $10,899.17 | 2023-2025 | Trogarzo, Egrifta |
| Janssen Research & Development, LLC | $3,720.00 | 2021 | |
| Shionogi INC | $2,600.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Flexner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.